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Abstract
Background: Proteasomes play a central role in the major histocompatibility class I (MHCI) antigen processing
pathway. They conduct the proteolytic degradation of proteins in the cytosol, generating the C-terminus of CD8 T
cell epitopes and MHCI-peptide ligands (P1 residue of cleavage site). There are two types of proteasomes, the
constitutive form, expressed in most cell types, and the immunoproteasome, which is constitutively expressed in
mature dendritic cells. Protective CD8 T cell epitopes are likely generated by the immunoproteasome and the
constitutive proteasome, and here we have modeled and analyzed the cleavage by these two proteases.
Results: We have modeled the immunoproteasome and proteasome cleavage sites upon two non-overlapping
sets of peptides consisting of 553 CD8 T cell epitopes, naturally processed and restricted by human MHCI
molecules, and 382 peptides eluted from human MHCI molecules, respectively, using N-grams. Cleavage models
were generated considering different epitope and MHCI-eluted fragment lengths and the same number of
C-terminal flanking residues. Models were evaluated in 5-fold cross-validation. Judging by the Mathew’s Correlation
Coefficient (MCC), optimal cleavage models for the proteasome (MCC = 0.43 ± 0.07) and the immunoproteasome
(MCC = 0.36 ± 0.06) were obtained from 12-residue peptide fragments. Using an independent dataset consisting of
137 HIV1-specific CD8 T cell epitopes, the immunoproteasome and proteasome cleavage models achieved MCC
values of 0.30 and 0.18, respectively, comparatively better than those achieved by related methods. Using ROC
analyses, we have also shown that, combined with MHCI-peptide binding predictions, cleavage predictions by the
immunoproteasome and proteasome models significantly increase the discovery rate of CD8 T cell epitopes
restricted by different MHCI molecules, including A*0201, A*0301, A*2402, B*0702, B*2705.
Conclusions: We have developed models that are specific to predict cleavage by the proteasome and the
immunoproteasome. These models ought to be instrumental to identify protective CD8 T cell epitopes and are
readily available for free public use at http://imed.med.ucm.es/Tools/PCPS/.
Background
CD8 cytotoxic T cells play a key role fighting intracellular
pathogens, eliminating infected cells that display on their
cell surface foreign peptides bound to major histocom-
patibility complex class I (MHCI) molecules [1-3]. CD8
T cell epitopes and, in general, peptides presented by
MHCI molecules, derive from protein fragments pro-
duced in the cytosol by the proteolytic action of the
proteasome [4,5]. Briefly, the proteasome generates pro-
tein fragments between 7 and 15 amino acids. Some of
these peptides can be transported from the cytosol into
the endoplasmic reticulum (ER) by the transporter asso-
ciated with antigen processing (TAP), where they can be
loaded onto nascent MHCI molecules. Interestingly,
whereas different peptidases and proteases in the cytosol
and the endoplasmic reticulum shape the N-terminus of
the peptides presented by MHCI molecules [6], their
C-terminus generally corresponds to the P1 residue of
the proteasome cleavage site [7,8].
The proteasome is a multisubunit ATP-dependent pro-
tease and it is primarily responsible for the degradation
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proteasome is known as the 26 S proteasome, which is
composed by a catalytic core (20S) and two regulatory
complexes (19S), located one at each side of the core [5].
The catalytic activity of the proteasome is located at the
subunits b5( X ,L M P 7 ) ,b2( Z ,M E C L - 1 )a n db1
(Y, LMP2) of the 20 S core, which cut after the C-termi-
nus of hydrophobic (chymotrypsin-like activity), basic
(trypsin-like activity) or acidic (caspase-like activity)
amino acids, respectively [10]. Upon IFN-g exposure, the
three catalytic subunits of the constitutive 20 S core can
be replaced by three new catalytic subunits: b5i (LMP2),
b2i (MECL-1), and b1i (LMP2) [11]. This new form of
proteasome is called immunoproteasome, as opposed to
the constitutively expressed proteasome. The immuno-
proteasome is the constitutive form of proteasome pre-
sented in dendritic cells [12]. The immunoproteasome
produces different but overlapping cleavage patterns with
regard to those of the proteasome [13]; chiefly, the
immunoproteasome does not cut after acidic residues
[13,14]. Because the antigen-specific cytotoxic function
of CD8 T cells is generally acquired upon the recognition
of MHCI-bound peptide antigens displayed on the cell
surface of dendritic cells (priming), it is likely that protec-
tive epitopes are those generated by the proteasome and
the immunoproteasome [15].
Prediction of proteasome cleavage sites is relevant for
CD8 T cell epitope identification and, subsequently,
for the design of epitope-based vaccines eliciting CD8
T cell responses. Therefore, different methods to predict
proteasome cleavage sites have been reported. Protea-
some cleavage prediction methods were first developed
using enolase and b-casein protein fragments generated
in vitro by human constitutive proteasomes [16-18].
Likewise, a kinetic model of the proteasome proteolytic
activity was also developed using peptide fragments
from in vitro digestions [19,20]. Those models are speci-
fic for the constitutive 20 S proteasome that was used
to generate the peptide fragments. Proteasome cleavages
take place between the C-terminus of MHCI-restricted
peptides (P1 residue of cleavage site) and their most
proximal C-terminal flanking residue (P1’ residue of
cleavage site). Therefore, proteasome cleavage prediction
methods have also been developed using MHCI-
restricted peptide ligands and their C-terminal flanking
regions [21-23]. These latter methods appear to out-
compete the former methods that were trained on
actual proteolytic digestion data on the task of predict-
ing cleavage sites defined by MHC I restricted peptides
[24]. However, methods trained on experimental clea-
vage data can be more suitable for identifying protein
fragments produced by the proteasome [18].
The problem of predicting proteasome cleavage sites
resembles that of modeling grammatical rules. Therefore,
in this manuscript, we have applied statistical language
models [25] to analyze and model the cleavage sites of
the constitutive proteasome and the immunoproteasome.
Proteasome cleavage sites were obtained from MHCI-
eluted peptides and their C-terminal flanking regions,
whereas immunoproteasome cleavage sites were ren-
dered from naturally processed CD8 T cell epitopes and
their C-terminal flanking regions. In cross-validation,
optimal proteasome and immunoproteasome cleavage
models achieved an MCC of 0.43 ± 0.07 and 0.36 ± 0.06,
respectively. These models were trained using 12-residue
fragments, consisting of the C-terminal end of MHCI-
restricted peptides (P6 - P1 residues of cleavage site)
followed by the 6 most-proximal C-terminal flanking
residues (P1’ - P6’ residues of cleavage site). The fact
that optimal models were trained using peptide frag-
ments consisting of 6 amino acids at each side of the
cleavage site is consistent with the activity exhibited by
the proteasome [26]. Here, we have also shown that com-
bining cleavage predictions by the constitutive and the
immunoproteasome with MHCI-binding predictions
serve to improve the prediction rate of CD8 T cell
epitopes. Cleavage predictions using our models are
available at http://imed.med.ucm.es/Tools/PCPS/.
Methods
Datasets and sequences
We assembled three non-overlapping datasets consisting
of distinct MHCI-restricted peptides and their protein
sources. The peptide content in these datasets was as
follows. The first dataset encompassed 553 CD8 T cell
epitopes from different sources but from Human Immu-
nodeficiency Virus (HIV1) and were all restricted by
human MHCI molecules. Immune responses against
these epitopes have been verified experimentally using
T cells from infected humans. Because CD8 T cell
immune responses against these epitopes are elicited in
the course of an infection, we assume that they are natu-
rally processed. The second dataset included 382 peptides
that were eluted from human MHCI molecules, and the
third dataset encompassed 137 HIV1-specific CD8 T cell
epitopes restricted by human MHCI molecules and
naturally processed. MHCI-restricted peptides in these
datasets were collected from the EPIMHC [27], Immu-
neepitope [28] and Los Alamos databases [29], and con-
sisted of unique nonapeptides (9-mers) that were
subjected to a sequence similarity reduction schema
using the purge utility implemented in the Gibbs Sampler
[30]. As a result, peptides in these three datasets do not
share more than 4 identical residues (global sequence
similarity in the first, second and third datasets is 3.1 ±
11.7, 3.9 ± 12.8, and 3.5 ± 11.7, respectively). Moreover,
in all datasets the same MHCI molecule restricts less
than 18% of all peptides. In additional file 1, we show the
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of the three datasets. The corresponding author will also
provide these datasets upon written request.
Model building and evaluation
Cleavage models were trained and evaluated on datasets
consisting of peptide fragments of the same length derived
from MHCI-eluted peptides (proteasome models) and
CD8 T cell epitopes (immunoproteasome models) and
their C-terminal flanking regions, using the NGRAM-
COUNT utility implemented by the SRILM package [25].
Peptide fragments encompassed two portions with the
same number of residues, one fraction consisting of the C-
terminal end of MHCI-eluted peptides or CD8 T cell epi-
topes, and the other one of their C-terminal flanking
region. Cleavage sites -defined between the C-terminus of
MHCI-restricted peptides (P1 residue of cleavage site) and
the most proximal C-terminal flanking residue (P1’ resi-
due)- were indicated by a “|” symbol. Cleavage models
were generated considering peptide fragments ranging
from 4 to 18 residues. Representative peptide fragments of
6 and 12 amino acids are C T L | T I G and P S C C T L |
T I G V S S, respectively, where C T L and P S C C T L
are two C-terminal portions of the peptide and T I G and
T I G V S S are C-terminal flanking residues drawn from
the protein source. Cleavage models were tested and eval-
uated at different thresholds using the SRLIM HIDDEN-
NGRAM utility. HIDDEN-NGRAM is a word boundary
program that uses N-gram models [25] produced by
NGRAM-COUNT to predict the probability of hidden
tags -cleavage sites- in any peptide fragment. The evalua-
tion of the models was carried out through 5-fold cross-
validation experiments that were repeated 5 times, obtain-
ing mean estimations and standard deviations of the mea-
sures of performance indicated below.
Measures of performance
Cleavage predictions were examined in each residue at
different probability thresholds (th) and were judged fol-
lowing the schema proposed in previous works [22,24].
It is assumed that cleavage sites should preferentially
occur after the C-terminus of MHCI-restricted peptides
(P1 residue of cleavage site) than over any other position
within the peptide. Under such schema, any given test
peptide was classified as follows:
- TP (True positive): Cleavage score at the C-termi-
nus (P1 residue of cleavage site) is above the th.
- FN (False negative): Cleavage score of P1 residue is
below the th.
- TN (True negative): All the residues within the test
fragment have a cleavage score bellow the th.A l t e r -
natively, if there are residues with cleavage scores
above the th, but smaller than that of the P1 residue.
- FP (False positive): There is at least one residue
within the peptide with a cleavage score that is both,
above the th and above that of the P1 residue.
Upon this classification approach, we computed the
Sensitivity (SE), Specificity (SP) and Matthews correla-
tion coefficient (MCC)[ 3 1 ]o ft h ep r e d i c t i o n su s i n g
Equations 1, 2 and 3, respectively,
SE
TP
TP FN
=
+
(1)
SP
TN
TN FP
=
+
(2)
MCC
TP TN FN FP
TN FN TP FN TN FP TP FP
= () −()
+ () + () + () + ()
**
(3)
In addition, we also computed the parameter BTR
(Better Than Random) which was first introduced by
Reche et al. [32] to compare the SE of a given model
and that of a random model producing the same num-
ber of cleavage sites (Equation 4).
BTR SE ECS =− (4)
ECS (Expected Cleavage Sites) represents the ratio of
cleavage sites correctly predicted by a model that distri-
butes cleavage sites randomly and is given by Equation 5.
ECS
C
FN
=
*
(5)
Where C is the total number of cleavage sites (above
the th) predicted by a given cleavage model in a test set
of peptide fragments -specifically, within the MHCI-
restricted peptide portion of the peptide fragment-; F is
the number of MHCI-restricted peptide residues
included in the peptide fragments used for training and
testing; and N is the total number of peptide fragments
in the dataset. Note that peptide fragments used for
model building and evaluation encompassed two portions
with the same number of residues, one consisting of the
C-terminal end of MHCI-restricted peptides and the
other of their C-terminal flanking region (details else-
where in Methods). ECS is somewhat equivalent to the
SE of a model that distributes all the cleavage sites ran-
domly. Thus, the bigger the difference between SE and
ECS the better the predictions produced by the model.
Prediction of peptide binding to MHCI
We used Position Specific Scoring Matrices (PSSMs) to
compute binding scores of peptides to the relevant
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particular MHCI molecule was assessed relating its
binding score to those of 10000 reference peptides, 9-
mers randomly obtained from SwissProt, computed
using the same relevant PSSM. Thus, a given peptide
was considered to bind a specific MHCI molecule when
its binding score ranked among the X percentile (thresh-
old) of top binding scores. The same peptide was con-
sidered not to bind to that MHCI if it ranked below the
X percentile of top binding scores. PSSMs are derived
from alignments of peptides of the same size known to
bind to a given MHCI molecule [32,34,35]. Given that
MHCI-bound peptides are usually of 9 residues of
length, in this study we used PSSMs specific for the pre-
diction of peptide binders of that length (9mers).
ROC analysis
We used 5 different sets of CD8 T cell epitopes consisting
of 316, 50, 70, 47 and 30 peptides restricted by A*0201,
A*0301, A*2402, B*0702, and B*2705, respectively, to eval-
uate the discovery rate of CD8 T cell epitopes using
MHCI peptide-binding predictions alone, or in combina-
tion with proteasome cleavage predictions. Receiver oper-
ating characteristic (ROC) curves [36] were used to
analyze the predictions. In the ROC analysis, we repre-
sented the SE (Equation 1) versus 1-SP (Equation 2) of the
T cell epitope predictions obtained over a continuous
range of percentile thresholds of MHCI binding (detail
elsewhere in Methods). Non-T cell epitopes, required to
compute the SP of the predictions, consisted of peptides
of 9 residues randomly selected from the SwissProt data-
base. A 1:3 ratio of T cell epitopes to non-T cell epitopes
data was used. When evaluating the combination of
MHCI binding and proteasome cleavage predictions, we
applied a filtering approach such as that used by Dönnes
and Kohlbacher [37]. Under this approach, peptides that
are not predicted to be cleaved by the proteasome are dis-
carded prior to the ROC analysis.
The area under ROC curves (AUC) was used as a glo-
bal threshold-independent measure of performance. The
maximum accuracy corresponds to an AUC = 1 while
an AUC = 0.5 is indicative of a random prediction. Pre-
dictions are poor for values of AUC > 0.7, good for
values of AUC > 0.8 and excellent for values of AUC >
0.9. ROC analyses were repeated 10 times, using the
same T cell epitopes but different non-T cell epitopes.
Thus, we obtained confident values of AUC (mean and
standard deviation). Statistical significance of the differ-
ences between AUC values was evaluated using standard
one-side two sample Student t- tests (p < = 0.05).
Web implementation
Immunoproteasome and proteasome cleavage models
were implemented for free public use on the Web using a
PERL CGI (Common Gateway Interface) script that
executes the predictions on user-provided input data and
returns the results to the browser. In addition, we used
JavaScript for handling and verification of the input data
before submission. Proteasome and immunoproteasome
cleavage models exhibited optimal predictions at different
model-specific cleavage scores. Therefore, cleavage scores
by the different models were normalized and standardized
so that cleavage sites are predicted at a score ≥ 0.5.
Results
Proteasome and immunoproteasome cleavage models
Cleavage models were generated from two types of
MHCI-restricted peptides and their flanking regions
using N-grams. N-gram models are frequently applied to
speech recognition and natural language tagging [38],
but they have also been applied to sequence analysis
and motif identification [32,39-41]. We built two types
of cleavage models. Immunoproteasome cleavage models
were built upon a dataset encompassing 553 CD8 T cell
epitopes that have been reported to be recognized by
h u m a n sd u r i n gt h ec o u r s eo f an infection. Epitope-
specific CD8 T cell responses are generally primed by
dendritic cells which express the immunoproteasome.
Therefore, naturally processed CD8 T cell epitopes can
be used to reproduced the cleavage by the immunopro-
teasome. In contrast, proteasome cleavage models were
based on a set of 382 peptides that were eluted from
human MHCI molecules. Peptide elution experiments
are generally carried out using various types of cells
(virtually never dendritic cells) and under conditions
that do not induce the expression of the immunoprotea-
some. Therefore, we considered that MHCI-eluted pep-
tides are produced by the proteasome. A detailed
description of these datasets is elsewhere in Methods.
Numerous immunoproteasome and proteasome clea-
vage models were obtained from different training sets
consisting of peptide fragments varying from 4 to 18 resi-
dues -in a given training set, all the peptides have the
same size. Peptide fragments used for training included
the C-terminus (P1 residue of cleavage site) of MHCI-
restricted peptides (CD8 T cell epitopes and MHCI-
eluted peptides) and comprised two distinct portions
with the same number of residues: one consisting of the
C-terminal end of MHCI-restricted peptides and the
o t h e ro n eo ft h e i rC - t e r m i n a lf l a n k i n gr e g i o n( s e eM e t h -
ods section for more details). Cleavage models were eval-
uated in 5-fold cross-validation experiments, considering
a continuous range of cleavage thresholds. As measures
of performance we computed SE, SP, MCC and BTR (see
Methods section for details), but trusted BTR as the key
measure of the goodness of the predictions. In Figure 1A
we show the optimal BTR achieved by the cleavage mod-
els with regard to the size of the peptide fragments used
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the cleavage models, which also includes the MCC, SE,
SP of the predictions, is shown in Table 1.
The predictive performance of the cleavage models
significantly increased (p < 0.05) with the length of the
peptide fragments used for training, picking at a fragment
size of 12-14 residues (Figure 1A); BTR = 0.44 ± 0.02 for
the immunoproteasome model and BTR = 0.53 ± 0.02 for
the proteasome model. In general, the predictive perfor-
mance of proteasome cleavage models built upon MHCI-
eluted peptides was higher than that achieved by immuno-
proteasome cleavage models, regardless of the length the
peptides fragments used for training (Figure 1A). Increas-
ing the size of the peptide fragments beyond 14 residues
did not improve the predictive performance of the clea-
vage models (Figure 1A). Judging the predictions by
the MCC, the immunoproteasome and proteasome mod-
els that were built on peptide fragments of 12 residues
(Table 1) achieved the best results. Because no statistical
difference was observed between the BTR achieved by the
models trained on 12 and 14 residues, for further analysis,
we used the models trained on 12-residue peptide frag-
ments. The performance of the selected proteasome and
immunoproteasome models is summarized in Figure 1B.
Comparison of the immunoproteasome and proteasome
cleavage models
For further comparisons, we evaluated the immunoprotea-
some and proteasome cleavage models in an independent
test set built from 137 HIV1-specific CD8 T cell epitopes
and their flanking regions (Figure 2). The immunoprotea-
some model achieved better results than the proteasome
model, as judged by both, the BTR (0.45 for the immuno-
proteasome model and 0.39 for the proteasome model)
and the MCC (0.30 for the immunoproteasome model and
0.18 for the proteasome model). These results indicate
that the immunoproteasome model appears to be more
suitable than the proteasome model to predict the clea-
vage sites defined by CD8 T cell epitopes.
Using the immunoproteasome and proteasome clea-
vage models, we analyzed the fragmentation patterns
resulted from 100 proteins randomly selected from the
SwissProt database (Figure 3). The immunoproteasome
cleavage model generated fragments with a mean size of
2.23 ± 1.61 residues, whereas the proteasome cleavage
model generated fragments with a mean size of 3.02 ±
2.33 residues. Using a Wilcoxon test, we observed no
significant difference between the sizes of the fragments
generated with the proteasome and immunoproteasome
models (Figure 3A). This analysis also revealed that 36%
of the peptide fragments generated by the proteasome
and immunoproteasome are identical, and 67% of the
cleavage sites are shared (Figure 3B).
Comparison with NetChop
We also used the 137 HIV1-specific CD8 T cell epitopes
and their flanking regions to compare the cleavage pre-
dictions obtained with our N-gram cleavage models and
those obtained using the NetChop web sever. The
NetChop system uses an artificial neural-network model
Figure 1 Evaluation of immunoproteasome and proteasome prediction models. The predictive performance of proteasome models was
evaluated in 5 fold cross-validation experiments using MCC, BTR, SP and SE as measures of performance. Proteasome models were built and
tested using MHCI-eluted peptide ligands whereas immunoproteasome models were built and tested using MHCI-restricted CD8 T cell epitopes.
A) Predictive performance (BTR) achieved by immunoproteasome (grey line) and proteasome (black line) models trained and tested on peptides
of different fragment lengths (abscissa). Statistically significant increments in BTR are indicated with “*” symbols. B) Predictive performance (BTR,
MCC, SP, SE) achieved by the selected proteasome and immunoproteasome models built on peptide fragments of 12 residues.
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Immunoproteasome
Size SE SP ECS MCC BTR
4 0.807 ± 0.030 0.851 ± 0.039 47.828 ± 2.001 0.660 ± 0.038 0.329 ± 0.016
6 0.763 ± 0.036 0.708 ± 0.042 38.495 ± 0.614 0.472 ± 0.069 0.378 ± 0.016
8 0.906 ± 0.023 0.545 ± 0.038 51.219 ± 1.008 0.484 ± 0.059 0.394 ± 0.011
10 0.802 ± 0.024 0.462 ± 0.019 39.083 ± 1.003 0.281 ± 0.045 0.411 ± 0.012
12 0.903 ± 0.031 0.407 ± 0.031 46.339 ± 0.481 0.357 ± 0.062 0.439 ± 0.014
14 0.872 ± 0.035 0.374 ± 0.023 43.190 ± 1.498 0.284 ± 0.056 0.434 ± 0.017
16 0.855 ± 0.030 0.306 ± 0.041 41.908 ± 1.406 0.193 ± 0.047 0.436 ± 0.015
18 0.857 ± 0.031 0.290 ± 0.028 42.536 ± 1.081 0.179 ± 0.039 0.432 ± 0.015
Proteasome
Size SE SP ECS MCC BTR
4 0.803 ± 0.125 0.871 ± 0.052 44.110 ± 9.249 0.681 ± 0.089 0.362 ± 0.069
6 0.792 ± 0.048 0.723 ± 0.037 36.274 ± 1.943 0.516 ± 0.082 0.429 ± 0.023
8 0.855 ± 0.037 0.603 ± 0.047 38.160 ± 2.112 0.473 ± 0.072 0.473 ± 0.019
10 0.885 ± 0.050 0.537 ± 0.046 37.839 ± 2.355 0.452 ± 0.069 0.506 ± 0.025
12 0.874 ± 0.034 0.534 ± 0.062 34.970 ± 1.704 0.434 ± 0.075 0.526 ± 0.017
14 0.871 ± 0.037 0.468 ± 0.065 33.699 ± 1.432 0.371 ± 0.085 0.532 ± 0.018
16 0.844 ± 0.058 0.403 ± 0.065 32.657 ± 1.692 0.276 ± 0.096 0.518 ± 0.027
18 0.794 ± 0.077 0.392 ± 0.060 27.510 ± 1.978 0.206 ± 0.126 0.519 ± 0.035
Cleavage models were built on peptide fragments of a given size encompassing the C-terminal end of MHCI-eluted ligands (proteasome model) or CD8 T cell
epitopes (immunoproteasome) and the corresponding C-terminal flanking residues. Predictive performance was evaluated in 5-fold cross-validation experiments.
SE: sensitivity; SP: specificity; MCC: Matthew’s correlation coefficient; BTR: better than random (Eq. 4).
Figure 2 Model evaluation using an independent test dataset. The proteasome and immunoproteasome models were evaluated using an
independent test consisting of HIV1-specific CD8 T cell epitopes. The predictive performance was evaluated using BTR (black bars), MCC (grey
bars), SP (white bars) and SE (pattern bars).
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this comparison, we used NetChop default settings (clea-
vage sites occur after residues having a probability of 0.5
or higher) in computing the SE, SP, and MCC of the pre-
dictions following the same schema reported by the
NetChop developers [22] (see Methods section for
details). In addition, we computed the BTR parameter
defined in this study. Because NetChop models were
trained on 18-residue peptide fragments consisting of
full-length MHCI-restricted peptides (9 residues) and the
most proximal 9 residues flanking the C-terminus, in this
comparison we evaluated SE, SP, MCC and BTR on pep-
tide fragments consisting of the full-length HIV1-specific
CD8 T cell epitopes. Note that in previous analyses these
parameters were evaluated on the portion of the peptide
fragments corresponding to the MHCI-restricted pep-
tides. The results of this analysis are depicted in Figure 4.
The immunoproteasome and proteasome N-gram models
achieved MCC values (0.20 and 0.19, respectively) similar
to those obtained using NetChop (0.18). Likewise,
NetChop and our N-gram models achieved similar BTR
values around 0.44 (Figure 4).
Combination of MHCI-peptide binding and cleavage
predictions
We also evaluated the impact of combining cleavage and
MHCI-peptide binding predictions on T cell epitope
identification. Specifically, using a ROC analysis (see
Methods section for details), we analyzed the result of
such combination to discriminate CD8 T cell epitopes
restricted by 5 different MHCI molecules (A*0201,
A*0301, A*2402, B*0702 and B*2705) from random pep-
tides. We combined MHCI-peptide binding predictions
with cleavage predictions by the immunoproteasome
and proteasome models, individually or together, and
used AUC values (computed after the ROC analyses, see
Methods for details) as a measure of the goodness of
the predictions (Figure 5).
MHCI-peptide binding predictions alone achieved
high AUC values above 0.9 -regardless of the MHCI
molecule-, that did not leave much margin to observe
any large improvements on CD8 T cell epitope predic-
tions. Nevertheless, combining the proteasome and
immunoproteasome models separately or together with
MHCI-peptide binding predictions resulted in
increased AUC values (Figure 5B). Moreover, such
increases were statistically significant (p <0 . 0 5 )i na l l
cases. The major increment in AUC was observed for
A*0301-restricted epitopes. Alone, MHCI-peptide bind-
ing predictions reached an AUC = 0.9063 ± 0.0141 for
A*0301, whereas in combination with the immunopro-
teasome and proteasome cleavage predictions achieved
AUC values of 0.9416 ± 0.017, and 0.9411 ± 0.0095,
respectively.
Figure 3 Analysis of fragmentation patterns produced by the immunoproteasome and proteasome models. A) BoxPlot of the fragment
size distribution obtained with the immunoproteasome and the proteasome models. Not significant difference was observed, using a Wilcoxon
test, between the sizes of the fragments generated by each model B) Overlap between the fragments generated by the immunoproteasome
and proteasome models represented as the percentage of common sites (black bar) and the percentage of common fragments (grey bar).
Fragments were obtained from 100 proteins randomly selected from the Swissprot database. We used the optimal proteasome and
immunoproteasome models, which were built on 12-residue peptide fragments.
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obtained combining MHCI-peptide binding and the
cleavage predictions by the immunoproteasome model
or the proteasome model, but the joint combination of
both cleavage models (immunoproteasome and protea-
some) with the MHCI-peptide binding resulted in AUC
values larger than those obtained using single cleavage
models (Figure 5B). Nevertheless, with the exception of
A*0201 (p < 0.05), these increases in AUC were not sta-
tistically significant with regard to those AUC obtained
using solely either cleavage model (Figure 5B).
Enhanced AUC values obtained upon combining the
cleavage models with MHCI-peptide binding predictions
are due to the reduction of the number of false positives
detected with regard to the MHCI-peptide binding pre-
dictions alone (Figure 5C). Taking MHCI-peptide bind-
ing predictions alone as reference, we observed a ~56%
decrease of false positives (computed over the entire
range of thresholds used in the ROC analysis) when
using the immunoproteasome model. The reduction of
false positives was even larger (68%) when using the
proteasome model and increased slightly when both
models were combined (70%).
Proteasome Cleavage Prediction Server (PCPS)
We developed PCPS (Proteasome Cleavage Prediction
Server) to allow the prediction of proteasome and
immunoproteasome cleavage through our N-gram
models. PCPS is available for free public use at http://
imed.med.ucm.es/Tools/PCPS/. PCPS was designed to
be intuitive and user friendly (Figure 6A). The main
input data for PCPS is one or several protein sequences
that can be pasted or uploaded to the server in multiple
formats, including FASTA, IG, GenBank, EMBL, Phylip,
N B R F ,G C G ,D N A S t r i d e r ,P I R ,M S F ,A S Na n dP A U P .
The sequences provided to the server are subjected to a
cleavage analysis using N-gram models that are selected
by the user from the CLEAVAGE MODELS section.
There are several models available for both proteasomes,
constitutive and immunoproteasome, which differ in
sensitivity and specificity, and users can combine differ-
ent proteasome and immunoproteasome models. Clea-
vage models in PCPS were trained on peptide fragments
of 12 (models 1), 8 (models 2) and 6 (models 3) residues.
The models trained on 12 residues exhibited the best
performance (MCC = 0.43 ± 0.07 for the proteasome
cleavage model and MCC = 0.36 ± 0.06 for the immu-
noproteasome cleavage model) (Table 1). The output of
PCPS consists of a table indicating the cleavage score of
each residue in the protein queries (Figure 6B). Com-
puted scores reflect the likelihood that the proteasome/
immunoproteasome would cleave the protein after such
residue (P1 residue of cleavage site). Whenever the clea-
vage score is higher than 0.5, a tick marks the corre-
sponding residue. The different models actually differ in
the sensitivity, specificity, and BTR of the predictions.
Figure 4 Comparative analysis of cleavage predictions. The figure depicts the MCC (black bars)a n dt h eBTR (grey bars)a c h i e v e db yo u r
immunoproteasome and proteasome models and NetChop on an independent test set of 137 HIV1-specific CD8 T cell epitopes. Because
NetChop was built using complete nonameric MHCI-restricted peptides, in this analysis we have evaluated the cleavage predictions by the three
models over the entire length of the T cell epitopes being tested.
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models were achieved at cleavage thresholds of 0.5, but
users can experiment with the server and decide differ-
ent cleavage thresholds.
Discussion
It is generally believed that the C-terminus of most CD8
T cell epitopes, and in general that of most MHCI-
restricted peptides, results from the proteolytic cleavage
by the proteasome [4,9]. Some other proteases, chiefly
tripeptidyl peptidase II (TPP II), also play some role
generating the C-terminus of some MHCI-restricted
peptides[42-44], specifically through the degradation of
some proteolytic products generated by the proteasome
that are longer than 15 residues [43]. However, because
the majority of the peptide fragments generated by the
proteasome are shorter than 15 residues [13], the pro-
teasome is still the principal source of the C-terminus of
peptides that are bound to MHCI molecules. As a result,
proteasome cleavage models can be derived using clea-
vage sites recreated from MHCI-restricted peptides and
their C-terminal flanking regions [21-23].
There are two types of proteasomes, the immunopro-
teasome and the constitutive proteasome, which differ in
their cleavage patterns [14]. The constitutive proteasome
is the form expressed in most nucleated cells, whereas
the immunoproteasome is constitutively expressed in
mature dendritic cells. Antigen presentation by dendritic
cells is generally required to prime and instruct naïve
CD8 T cells in an antigen specific manner. Subsequently,
the effector function of CD8 T cells is executed upon
recognizing the same antigenic peptides on target cells
[45]. Consequently, the immunoproteasome is responsi-
ble for the generation of the C-terminus of the peptides
that elicit the CD8 T cell response, whereas the constitu-
tive proteasome determines the C-terminus of the
MHCI-peptide ligands that can be the targets of such
response. Protective CD8 T cell epitopes are likely those
generated by both, the constitutive proteasome and the
immunoproteasome [15].
In this work, we have assumed that MHCI-eluted pep-
tides reflect protein degradation by the proteasome,
whereas bona fide identified CD8 T cell epitopes elicited
in patients during the course of an infection reflect protein
degradation by the immunoproteasome, but not necessa-
rily by the proteasome. The latter is due to the fact that
epitope verification is generally carried out by measuring
the response of T cells to synthetic peptides loaded onto
antigen presenting cells, which are seldom dendritic, thus
bypassing antigen processing by the proteasome in the test
target cells. Subsequently, using N-grams,w eh a v em o d -
eled the proteasome and immunoproteasome cleavage
Figure 5 Prediction of T cell epitopes using MHCI-peptide
binding and cleavage models. A) ROC curves depicting the
prediction of T cell epitopes restricted by A*0201 using MHCI-
peptide binding prediction alone (black line) or in combination with
cleavage predictions by the immunoproteasome (purple line), the
proteasome (grey line) and both cleavage models together (blue
line). B) AUC values obtained for the prediction of T cell epitopes
restricted by 5 different HLA I molecules (A*0201, A*0301, A*2402,
B*0702, B*2705) using MHCI-peptide binding predictions alone
(black bars) and in combination with cleavage predictions by the
immunoproteasome (purple bars), proteasome (grey bars) and both
cleavage models together (blue bars). Significant increases (p < 0.05)
in AUC values with regard to MHCI-peptide binding predictions
alone (black bars) are indicated with the symbol “*”. C) Reduction of
false positives. The figure represents the decrease in percentage of
false positives after introducing cleavage predictions by the
immunoproteasome (purple bars), the proteasome (grey bars) and
both together (blue bars). False positive reduction was computed
over the entire ROC analysis.
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Page 9 of 13from datasets of peptide fragments of different length built
upon MHCI-eluted peptides (proteasome model) and
CD8 T cell epitopes (immunoproteasome model) and
their C-terminal flanking regions. These models predict
whether the C-terminus of a given peptide, in the context
of its flaking residues, is likely to result from the proteoly-
tic activity of the proteasome and/or the immunoprotea-
some (P1 residue of cleavage site).
The best cleavage predictions for both proteasomes,
constitutive and immunoproteasome, were obtained
using N-grams trained on 12-residue peptide fragments,
encompassing the 6 most proximal flanking residues to
the C-terminus of the MHCI-restricted peptides pre-
ceded by 6 residues from the C-terminal end of the
MHCI-restricted peptides (Figure 1). These results are
consistent with reports indicating that proteasomes and
immunoproteasomes scrutinize between 10 and 12 resi-
dues [10,26]. In contrast, related methods for the predic-
tion of proteasome cleavage that are based on MHCI-
restricted peptides have been trained using 18 to 20
residue peptide fragments [19,21,23], which, makes
these models, regardless of the results, somewhat
artificial.
In cross-validation, the predictive performance of pro-
teasome models exceeded that of immunoproteasome
models; the best proteasome cleavage model achieved a
BTR = 0.53 ± 0.02 and an MCC = 0.43 ± 0.07, whereas
the best immunoproteasome model achieved a BTR =
0.44 ± 0.01 and an MCC = 0.36 ± 0.06. Despite that
both sets of peptides were subjected to the same
sequence reduction procedure (See Methods), these
results likely reflect that the set of CD8 T cell epitopes
is more numerous and arguably more diverse than the
set of MHCI-eluted peptide (see Results). Dendritic cells
exhibit non-classical pathways on antigen presentation
and some can be immunoproteasome independent
[45,46], which could actually account for a higher diver-
sity in the epitope dataset. Nonetheless, the best immu-
noproteasome model achieved better results than the
corresponding proteasome model when predicting the
cleavage sites encompassed by an independent set con-
sisting of HIV1-specific CD8 T cell epitopes (Figure 2).
Taking into account all the above, the immunoprotea-
some model appears to be the most suitable to predict
the C-terminus of CD8 T cell epitopes.
Our constitutive proteasome and immunoproteasome
models produced different but overlapping fragmentation
patters that mirror those observed experimentally [13];
68% of the cleavage sites (P1 residues) and 36% of the
fragments generated were identical (Figure 3B). However,
the fragments yielded by the immunoproteasome and
proteasome models were much smaller (2-3 residues)
Figure 6 Proteasome Cleavage Prediction Server (PCPS). A) PCPS interface. B) PCPS result page. The page returns the predicted cleavage
score after each residue of the protein query. The residues with a cleavage score above the threshold (0.5) are marked with a tick. These
residues correspond to the P1 residue of the cleavage site and determine the C-terminus of MHCI-restricted peptides.
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Page 10 of 13than those determined experimentally (7-9 residues)
[13,47]. The smaller fragment sizes produced by our
models may reproduce the clustering and overlapping of
epitopes found in protein regions [48]. On the other
hand, it is important to note that our models are
not meant, and are not suitable, to predict proteolytic
fragments, but to indicate whether the C-terminus of a
peptide can result from the cleavage produced by the
proteasome and/or the immunoproteasome. Proteasome
fragmentation patterns (the size of fragments) may be
better reproduced by methods trained on actual cleavage
data such as that by Tenzer et al [18].
Using a test set of HIV1-specific CD8 T cell epitopes,
we found that the predictive performance of our optimal
proteasome and immunoproteasome cleavage models
was comparable to that of NetChop [22]; a reference
method to predict proteasome cleavage sites [24] that it
was also developed from MHCI-restricted peptides. The
immunoproteasome and proteasome cleavage models
achieved MCC values of 0.20 and 0.19, respectively,
while NetChop achieved an MCC =0 . 1 8 .I ti sw o r t h
nothing that these results were obtained under condi-
tions that were optimal for NetChop. First, NetChop
was trained on peptide fragments encompassing full
length MHCI-restricted peptides [22], and here we have
evaluated and compared the cleavage predictions over
the entire epitope sequences. Note that we only used a
portion of the MHCI-restricted peptides for training
(6 residues). Second, the HIV1-specific CD8 T cell epi-
topes used for testing were not used for training our
N-gram models but were likely included in the NetChop
training dataset. It is also important to mention that
NetChop has been described as an immunoproteasome
cleavage prediction method, but in fact it was trained on
a dataset consisting of both, MHCI-eluted ligands and
CD8 T cell epitopes. As we have discussed here, CD8
T cell epitopes can be considered as generated by the
immunoproteasome. However, it is more appropriated
to consider MHCI-eluted peptides as generated by the
constitutive proteasome because they are obtained from
different type of cells but seldom from dendritic cells. In
sum, we have dealt with the prediction of proteasome
and immproteasome cleavage sites from MHC-restricted
peptides in a manner that is consistent with the
mechanism of antigen presentation and recognition, and
achieved a notorious performance.
Prediction of proteasome and immunoproteasome clea-
v a g es i t e su s i n go u rm o d e l si sa v a i l a b l ea th t t p : / / i m e d .
med.ucm.es/Tools/PCPS/. In addition, there are several
other online servers to predict proteasome cleavage,
which differ in the data and approach used for generating
the models [16,22,49]. Nonetheless, the problem of iden-
tifying proteasome cleavage sites with high precision is
still far from being solved. A simple manner to improve
the prediction of proteasome cleavage sites could likely
be achieved trough a meta-server that would arrive to a
consensus prediction from the available proteasome clea-
vage predictors. Such a consensus approach has resulted
successful in the also difficult task of predicting peptide
binding to MHC class II molecules [50].
It has been reported that proteasome prediction models
can improve T cell epitope identification when combined
with MHCI-peptide binding predictions [18,22,37,51,52].
Likewise, our proteasome and immunoproteasome mod-
els, separately or together, also served to improve CD8
T cell epitope discrimination when combined with MHCI-
binding predictions (Figure 5). The improvements, judged
by increases in AUC, could appear minor but were statisti-
cally significant (Figure 5), and were linked to a large
reduction of the number of false positives detected (up to
70%). Therefore, combining proteasome cleavage and
MHCI-peptide binding predictions would serve to
decrease the experimental toll involved in epitope identifi-
cation; there will be less peptides to be tested. The protea-
some cleavage model alone or juxtaposed with the
immunoproteasome model resulted in a significant loss of
true positives (up to 20%). Therefore, the proteasome clea-
vage model will be more useful on large-scale epitope
identification scenarios (e.g. predicting CD8 T cell epi-
topes from a large number of antigens). Finally, combining
cleavage predictions by both proteasomes, constitutive and
immunoproteasome, with MHCI-binding predictions
o u g h tt oh e l pd e f i n i n gp r o t e c t i v eC D 8Tc e l le p i t o p e s .
Overall, these results call for the integration of our protea-
some models with others taking into account TAP trans-
port and MHC binding, as already pioneered by other
authors [18,22,37,51,52].
Conclussion
We have derived N-gram models specific for the pro-
teasome and the immunoproteasome that are consis-
tent with the known biology of antigen presentation.
The proteasome models were built upon MHCI-eluted
peptides whereas the immunoproteasome models were
built upon CD8 T cell epitopes. The N-gram models
that exhibited the best performance were trained
on 12-residue peptides, 6 residues at each side of the
cleavage site, defined by the C-terminus of MHCI-
restricted peptides and the most proximal C-terminal
flanking residue. Finally, we have shown that combin-
ing cleavage predictions by the proteasome and immu-
noproteasome models with MHCI-binding predictions
improves CD8 T cell epitope prediction. Cleavage pre-
dictions using our N-gram models are available for
free public use at the PCPS site http://imed.med.ucm.
es/Tools/PCPS/.
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Adittional file 1: MHCI allele distribution in peptide datasets. The
figure depicts the percentage of peptides restricted by 7 commonly
expressed human MHCI alleles (A*0201, A*0301, A*1101, A*2402, B*0702,
B*0801, B*2705) in the three datasets used in this study.
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